Evidence map›Paper›PMID 35865102›Full record

ArticleActa pharmaceutica Sinica. B2022

Gold nanoparticle-directed autophagy intervention for antitumor immunotherapy

Siyue Zhang, Fangyuan Xie, Kaichun Li, He Zhang, You Yin, Yuan Yu, Guangzhao Lu, Shihao Zhang, Yan Wei, Ke Xu and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Siyue ZhangDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
Fangyuan XieDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
Kaichun LiDepartment of Oncology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
He ZhangDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
You YinDepartment of Neurology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Yuan YuDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
Guangzhao LuDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
Shihao ZhangKey Laboratory for Ultrafine Materials of Ministry of Education, Engineering Research Center for Biomedical Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
Yan WeiInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Ke XuInstitute of Translational Medicine, Shanghai University, Shanghai 200444, China.
Yan WuDepartment of Biomaterial, College of Life Sciences, Mudanjiang Medical University, Mudanjiang 157011, China.
Hong JinDepartment of Laboratory Medicine, Hongqi Hospital, Mudanjiang Medical College, Mudanjiang 157011, China.
Lan XiaoCentre for Biomedical Technologies, Queensland University of Technology, Brisbane QLD 4000, Australia.
Leilei BaoDepartment of Pharmacy, Shanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200433, China.
Can XuDepartment of Gastroenterology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Yulin LiKey Laboratory for Ultrafine Materials of Ministry of Education, Engineering Research Center for Biomedical Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
Ying LuDepartment of Pharmacy, Naval Medical University, Shanghai 200433, China.
Jie GaoChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Shanghai University · CNSecond Military Medical University · CNMudanjiang Medical University · CNQueensland University of Technology · AUShanghai Changzheng Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-associated macrophages (TAMs), one of the dominating constituents of tumor microenvironment, are important contributors to cancer progression and treatment resistance. Therefore, regulation of TAMs polarization from M2 phenotype towards M1 phenotype has emerged as a new strategy for tumor immunotherapy. Herein, we successfully initiated antitumor immunotherapy by inhibiting TAMs M2 polarization

Indexed as

Autophagy fluxCancer therapyGold nanoparticlesLysosomal damageM2 macrophageMacrophage polarizationNanomaterialsTumor-associated macrophages

Identifiers

PMID35865102
PMCPMC9293675
OpenAlexW4212892896

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.